New research shows a novel pill is helping people with advanced pancreatic cancer live longer. It’s not a cure, as the drug’s effects eventually waned. But it’s a very different kind of treatment than the chemotherapy that is a mainstay for these patients. Called daraxonrasib, the drug is designed to block a mutated protein that fuels most cases of pancreatic cancer, one of the deadliest types of cancer. The research was published Sunday in the New England Journal of Medicine and presented at an American Society of Oncology meeting. Maker Revolution Medicines will seek Food and Drug Administration approval.